Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence

NCT05412966 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Opioid Use Disorder

Interventions

DEVICE: PEAR-002B
DEVICE: reSET-O

Sponsor

Pear Therapeutics, Inc.

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]